Literature DB >> 27647437

A long non-coding RNA signature to improve prognosis prediction of gastric cancer.

Xiaoqiang Zhu1, Xianglong Tian1, Chenyang Yu1, Chaoqin Shen1, Tingting Yan1, Jie Hong2, Zheng Wang3, Jing-Yuan Fang4, Haoyan Chen5.   

Abstract

BACKGROUND: Increasing evidence suggests long non-coding RNAs (lncRNAs) are frequently aberrantly expressed in cancers, however, few related lncRNA signatures have been established for prediction of cancer prognosis. We aimed at developing alncRNA signature to improve prognosis prediction of gastric cancer (GC).
METHODS: Using a lncRNA-mining approach, we performed lncRNA expression profiling in large GC cohorts from Gene Expression Ominus (GEO), including GSE62254 data set (N = 300) and GSE15459 data set (N = 192). We established a set of 24-lncRNAs that were significantly associated with the disease free survival (DFS) in the test series.
RESULTS: Based on this 24-lncRNA signature, the test series patients could be classified into high-risk or low-risk subgroup with significantly different DFS (HR = 1.19, 95 % CI = 1.13-1.25, P < 0.0001). The prognostic value of this 24-lncRNA signature was confirmed in the internal validation series and another external validation series, respectively. Further analysis revealed that the prognostic value of this signature was independent of lymph node ratio (LNR) and postoperative chemotherapy. Gene set enrichment analysis (GSEA) indicated that high risk score group was associated with several cancer recurrence and metastasis associated pathways.
CONCLUSIONS: The identification of the prognostic lncRNAs indicates the potential roles of lncRNAs in GC biogenesis. Our results may provide an efficient classification tool for clinical prognosis evaluation of GC.

Entities:  

Keywords:  GSEA; Gastric cancer; LNR; LncRNAs; Survival

Mesh:

Substances:

Year:  2016        PMID: 27647437      PMCID: PMC5029104          DOI: 10.1186/s12943-016-0544-0

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  75 in total

1.  Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses.

Authors:  Ilaria Panzini; Lorenzo Gianni; Pier Paolo Fattori; Davide Tassinari; Manuela Imola; Paolo Fabbri; Valentina Arcangeli; Giuliana Drudi; Debora Canuti; Francesca Fochessati; Alberto Ravaioli
Journal:  Tumori       Date:  2002 Jan-Feb       Impact factor: 2.098

2.  Summaries of Affymetrix GeneChip probe level data.

Authors:  Rafael A Irizarry; Benjamin M Bolstad; Francois Collin; Leslie M Cope; Bridget Hobbs; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

3.  Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan.

Authors:  K Oba; S Morita; A Tsuburaya; Y Kodera; M Kobayashi; J Sakamoto
Journal:  J Chemother       Date:  2006-06       Impact factor: 1.714

4.  Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.

Authors:  Eva Lieto; Francesca Ferraraccio; Michele Orditura; Paolo Castellano; Anna La Mura; Margherita Pinto; Anna Zamboli; Ferdinando De Vita; Gennaro Galizia
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

5.  Relationship of XIST expression and responses of ovarian cancer to chemotherapy.

Authors:  Kuan-Chun Huang; Pulivarthi H Rao; Ching C Lau; Edith Heard; Shu-Kay Ng; Carolyn Brown; Samuel C Mok; Ross S Berkowitz; Shu-Wing Ng
Journal:  Mol Cancer Ther       Date:  2002-08       Impact factor: 6.261

Review 6.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

7.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

8.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

9.  Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer.

Authors:  Hiroaki Saito; Yoji Fukumoto; Tomohiro Osaki; Yoshinori Yamada; Kenji Fukuda; Shigeru Tatebe; Shunichi Tsujitani; Masahide Ikeguchi
Journal:  J Surg Oncol       Date:  2008-02-01       Impact factor: 3.454

10.  Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.

Authors:  John M Maris; Yael P Mosse; Jonathan P Bradfield; Cuiping Hou; Stefano Monni; Richard H Scott; Shahab Asgharzadeh; Edward F Attiyeh; Sharon J Diskin; Marci Laudenslager; Cynthia Winter; Kristina A Cole; Joseph T Glessner; Cecilia Kim; Edward C Frackelton; Tracy Casalunovo; Andrew W Eckert; Mario Capasso; Eric F Rappaport; Carmel McConville; Wendy B London; Robert C Seeger; Nazneen Rahman; Marcella Devoto; Struan F A Grant; Hongzhe Li; Hakon Hakonarson
Journal:  N Engl J Med       Date:  2008-05-07       Impact factor: 91.245

View more
  89 in total

1.  A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.

Authors:  Tian-Bao Huang; Chuan-Peng Dong; Guang-Chen Zhou; Sheng-Ming Lu; Yang Luan; Xiao Gu; Lei Liu; Xue-Fei Ding
Journal:  Int Urol Nephrol       Date:  2017-02-10       Impact factor: 2.370

2.  An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme.

Authors:  Meng Zhou; Zhaoyue Zhang; Hengqiang Zhao; Siqi Bao; Liang Cheng; Jie Sun
Journal:  Mol Neurobiol       Date:  2017-05-19       Impact factor: 5.590

Review 3.  The regulatory roles and potential prognosis implications of long non-coding RNAs in gastric cancer.

Authors:  Yue Wang; Fan Yang; Qing Yang
Journal:  Histol Histopathol       Date:  2019-12-03       Impact factor: 2.303

4.  Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family.

Authors:  Cunrong Chen; Lili Zhou; Hui Wang; Junnian Chen; Wen Li; Wei Liu; Mingjie Shen; Hongzhou Liu; Xiaomin Fu
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

5.  Development of Prognostic Evaluation Model to Predict the Overall Survival and Early Recurrence of Hepatocellular Carcinoma.

Authors:  Yue Zhong; Yong Yang; Lei He; Yang Zhou; Niangmei Cheng; Geng Chen; Bixing Zhao; Yingchao Wang; Gaoxiong Wang; Xiaolong Liu
Journal:  J Hepatocell Carcinoma       Date:  2021-04-29

Review 6.  Autophagy and gastrointestinal cancers: the behind the scenes role of long non-coding RNAs in initiation, progression, and treatment resistance.

Authors:  Rana Shafabakhsh; Farzaneh Arianfar; Massoud Vosough; Hamid Reza Mirzaei; Maryam Mahjoubin-Tehran; Hashem Khanbabaei; Hamed Kowsari; Layla Shojaie; Maryam Ebadi Fard Azar; Michael R Hamblin; Hamed Mirzaei
Journal:  Cancer Gene Ther       Date:  2021-01-11       Impact factor: 5.987

7.  Comprehensive Analysis of the Prognostic Signature of Mutation-Derived Genome Instability-Related lncRNAs for Patients With Endometrial Cancer.

Authors:  Jinhui Liu; Guoliang Cui; Jun Ye; Yutong Wang; Can Wang; Jianling Bai
Journal:  Front Cell Dev Biol       Date:  2022-04-01

8.  The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics.

Authors:  Feng Xiao; Jiayu Liu; Yongbo Zheng; Zhen Quan; Wei Sun; Yao Fan; Chunli Luo; Hailiang Li; Xiaohou Wu
Journal:  J Biomater Appl       Date:  2020-12-06       Impact factor: 2.646

9.  Silencing lncRNA XIST exhibits antiproliferative and proapoptotic effects on gastric cancer cells by up-regulating microRNA-132 and down-regulating PXN.

Authors:  Ping Li; Liuhua Wang; Pengfei Li; Fangyong Hu; Yi Cao; Dong Tang; Gang Ye; Hongbo Li; Daorong Wang
Journal:  Aging (Albany NY)       Date:  2020-11-05       Impact factor: 5.682

10.  SNP-mediated lncRNA-ENTPD3-AS1 upregulation suppresses renal cell carcinoma via miR-155/HIF-1α signaling.

Authors:  Jiangyi Wang; Yun Zou; Bowen Du; Wenzhi Li; Guopeng Yu; Long Li; Lin Zhou; Xin Gu; Shangqing Song; Yushan Liu; Wenquan Zhou; Bin Xu; Zhong Wang
Journal:  Cell Death Dis       Date:  2021-07-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.